-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3374 Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Program: Oral and Poster Abstracts
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Chemotherapy, Diseases, Treatment Considerations, Lymphoid Malignancies, Non-Biological therapies
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Laura Rosiñol Dachs, MD, PhD1*, Albert Oriol, MD, PhD2*, María-Jesús Blanchard, MD, PhD3*, Javier de la Rubia4*, Rafael Ríos, MD, PhD5*, Joan Bargay6*, Miguel Teodoro Hernández Garcia, MD, PhD7*, Valentín Cabanas Perianes8*, Ana López de la Guía9*, Estrella Carrillo-Cruz, MD10*, Anna Sureda Balari, MD, PhD11, Joaquin Martínez-López12*, Jose Maria Arguiñano, MD13*, Esther González García, MD, PhD14*, Luis Felipe Casado15*, Josep Maria Marti Tutusaus16*, Cristina Encinas17*, Felipe De Arriba, MD, PhD18*, Luis Palomera, MD, PhD19*, Antonia Sampol Mayol, MD20*, Yolanda González-Montes, MD, PhD21*, Jordi López-Pardo22*, Maialen Sirvent, PhD23*, Maria Belen Inigo Rodriguez24*, Bruno Paiva, PhD25*, Noemi Puig, PhD26, Maria Teresa Cedena Romero, MD, PhD27*, Norma C. Gutierrez28*, Javier De la Cruz, MD29*, Maria-Victoria Mateos, MD, PhD30, Jesús F. San-Miguel, MD, PhD31, Juan-Jose Lahuerta Palacios, MD, PhD32* and Joan Bladé, MD, PhD33*

1Hematology, IDIBAPS, Hospital Clinic, Barcelona, ESP
2Hematology, Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
3Hematology, Hospital Universitario Ramón y Cajal, Madrid, Spain
4Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
5Hospital Universitario Virgen De Las Nieves, Granada, ESP
6Hematology Department, Hospital Universitario Son Llàtzer. IdIsBa., Palma de Mallorca, Spain
7Hospital Universitario de Canarias, La Laguna, ESP
8Hospital Universitario Virgen de la Arrixaca., Murcia, Spain
9Hospital Universitario La Paz, Madrid, Spain
10Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain
11Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain
12Department of Hematology, Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, Madrid, Spain
13Complejo Hospitalario de Navarra, IdiSNA, Pamplona, Spain
14Hospital de Cabueñes, Gijón, Spain
15Hematology, Hospital General Universitario de Toledo, Toledo, Spain
16Hospital Universitari Mútua de Terrassa, Terrassa, Spain
17Hospital General Universitario Gregorio MarañóN, Madrid, Spain
18Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
19Hospital Clinico Universitario Lozano Blesa, Instituto Investigacion Sanitaria Aragon, Zaragoza, Spain
20Hematology Department., Hospital Universitario Son Espases, IdISBa., Palma, Spain
21Hematology, Institut d'Oncologia Dr. Josep Trueta, Girona, Spain
22Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
23Hospital de Donostia, San Sebastián, Spain
24HOSPITAL CLINICO SAN CARLOS, MADRID, Spain
25Department of Hematology, Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain
26Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
27Instituto de Investigación IMAS12, Madrid, Spain
28Hospital Universitario De Salamanca, IBSAL, Salamanca, Spain
29Hospital Universitario 12 De Octubre, Instituto De Investigación Sanitaria,, Madrid, Spain
30University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Salamanca, Spain
31Clínica Universitaria de Navarra, Pamplona, Spain
32Hematology, Hospital Universitario 12 de Octubre, Imas12, CIBERONC, Madrid, Spain
33Hospital Clinic, IDIBAPS, Barcelona, Spain

Introduction: In 2006 the Spanish Group (PETHEMA/GEM) conducted a randomized trial (GEM05menos65, NCT00461747) for transplant eligible patients with newly diagnosed multiple myeloma showing a significant improvement in progression free survival with induction with VTD compared to TD and combination chemotherapy plus bortezomib (VBMCP/VBAD/B) (Blood 2012) followed by maintenance (Leukemia 2017). In 2013 a randomized trial with VRD as pretransplant induction (GEM2012menos65, NCT1916252) (Blood 2019) followed by maintenance therapy (GEM2014MAIN, NCT02406144) were conducted (Blood 2023). We report here the long-term results of the GEM05 trial and compared with the GEM2012/GEM2014 studies.

Methods: the GEM05 trial enrolled 389 patients between April, 2006 and August 5, 2009. Patients were randomized to receive three induction regimens: six 4-week cycles of thalidomide and dexamethasone vs. six 4-week cycles of VTD (thalidomide 200 mg daily; dexamethasone 40 mg on days 1-4 and 9-12 plus intravenous [iv] bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11) vs. combination chemotherapy plus bortezomib (4 cycles of alternating VBMCP and VBAD chemotherapy followed by two cycles of iv bortezomib [VBMCP-VBAD/B]). All patients were planned to undergo ASCT with melphalan 200 mg/m2 (MEL-200) followed by maintenance therapy with thalidomide/bortezomib (TV) vs. thalidomide alone (T) vs. alfa-2b-interferon (IFN) for 3 years. GEM2012 was conducted from September, 2013 to November, 2015 and included 458 patients. Induction therapy consisted of 6 cycles of VRD (subcutaneous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each cycle; lenalidomide 25 mg/d on days 1 to 21; and dexamethasone 40 mg on days 1 to 4 and 9 to 12 at 4-week intervals). Then, patients were randomized to receive conditioning with BuMEL vs. MEL-200. Patients who achieved at least minimal response were included in the GEM14MAIN trial and randomized to receive maintenance therapy with lenalidomide and dexamethasone (Rd) or ixazomib plus Rd for at least 2 years. Patients harboring del17p, t(4;14) and/or t(14;16) were considered as high-risk cytogenetics (HR) and those without these cytogenetic abnormalities as standard-risk (SR). Patient characteristics at diagnosis and prognostic factors such as ISS, plasmacytomas and cytogenetics were similar in both, GEM05 and GEM2012 trials.

Results: After a median follow-up of 184.9 months (15.1 years), VTD resulted in a significantly longer PFS when compared with TD and VBMCP/VBAD/B (50.4 vs 28.4 vs 34.9 months, p=0.007) and in a significantly longer OS (10.5 vs 7.0 vs 7.5 years, p=0.02). At 15 years, 37.8% vs 25.7% vs 18.9% of the patients were alive with VTD vs TD vs VBMCP/VBAD/B. Maintenance with TV was associated with a better PFS (52.9 vs 42.7 vs 33.7 months, p=0.031) and better OS (9.3 vs 8.6 vs 6.9 years, p=0.05) from transplant than T and IFN. With a median follow-up of 101 months (8.1 years) these results were significantly improved in the GEM2012 study, with a median PFS of 77.5 months (p<0.001) and OS at 8 years of 70%, 58%, 47% and 45% with VRD, VTD, TD and VBMCP/VBAD/B, respectively (p<0.001). Patients with SR-cytogenetics had a PFS of 90 vs 53.3 vs 30.1 vs 43.2 months (p<0.001) and a median OS not reached vs 13.3 vs 9.4 vs 7.8 years (p<0.001) with VRD, VTD, TD and VBMVP/VBAD/V, respectively. In patients with HR-cytogenetics, no benefit in PFS (23 vs 15.3 vs 13.9 months, p=0.28) or OS (3 vs 4.3 vs 2.4 yrs, p=0.657) where observed with VTD, TD or VBMCP/VBAD. However, a significant improvement were observed with VRD, with a median PFS of 51.5 months (p<0.01) and OS not reached (p=0.005).

Conclusions: After over 15 years of follow-up, patients receiving VTD induction displayed a significantly longer OS than those receiving TD or VBMCP/VBAD/V. Of interest, patients with SR cytogenetics were those who benefit most of VTD while no differences in OS were observed in patients with HR cytogenetics between the 3 arms. VRD has improved the results obtained with VTD, with a median PFS of 77.5 vs 50.4 months and an OS at 8 years of 70% vs 58%. Patients who benefit most of VRD compared to VTD were those with HR cytogenetics. Finally, the incorporation of anti-CD38 monoclonal antibodies to VRD will likely result in further improvement of long-term outcome and in the fraction of operational cure.

Disclosures: Rosiñol Dachs: Janssen: Honoraria; BMS: Honoraria. Oriol: Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Menarini: Membership on an entity's Board of Directors or advisory committees. de la Rubia: Bristol-Myers Squibb: Honoraria; Takeda: Research Funding; Janssen: Honoraria, Speakers Bureau; GlaxoSmithKline: Honoraria, Research Funding, Speakers Bureau; Menarini: Honoraria; Oncopharm: Honoraria; Sanofi: Speakers Bureau; Pfizer: Speakers Bureau. Cabanas Perianes: Janssen: Honoraria; Pfizer: Honoraria. Martínez-López: Altum Sequencing: Current equity holder in private company; Pfizer: Honoraria; Janssen: Honoraria. González García: Pfizer: Honoraria. Casado: Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene: Honoraria; Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene, Loxo, ELVN: Research Funding; Janssen, Roche, Novartis, BMS, Amgen, Takeda, Pfizer, Incyte, Abbvie, GSK, Sanofi, BeiGene: Consultancy. Encinas: Janssen: Honoraria; Pfizer: Honoraria. De Arriba: Takeda: Consultancy, Honoraria; Janssen‐Cilag: Consultancy, Honoraria, Other: advisory board; Sanofi: Consultancy, Honoraria, Other: advisory board; GlaxoSmithKline (GSK): Consultancy, Honoraria, Other: advisory board; Amgen: Consultancy, Honoraria, Other: advisory board; Bristol‐Myers Squibb (BMS)/Celgene: Consultancy, Honoraria, Other: advisory board. Paiva: Aztra Zeneca, Bristol Myers Squibb/Celgene, EngMab, Roche, Sanofi, and Takeda: Research Funding; Bristol Myers Squibb/Celgene, Janssen, Sanofi, and Takeda: Consultancy; Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb/Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda: Honoraria. Puig: Pfizer, Sanofi, Amgen, BMS, Janssen, Takeda, and The Binding Site: Honoraria; Pfizer, Sanofi, Amgen, BMS-Celgene, Janssen, and Takeda: Consultancy. Cedena Romero: JANSSEN: Honoraria. Gutierrez: University Hospital of Salamanca: Current Employment; Amgen, Sanofi: Honoraria. Mateos: GSK: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Sanofi: Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Takeda: Consultancy; AbbVie: Consultancy, Honoraria; Kite: Consultancy. San-Miguel: Karyopharm: Other: Advisory board; MSD: Other: Advisory board; Novartis: Other; Takeda: Other: Advisory board; Regeneron: Other: Advisory board; Roche: Other: Advisory board; Sanofi: Other: Advisory board; Celgene: Other: Advisory board; GlaxoSmithKline: Other: Advisory board; Haemalogix: Other: Advisory board; Janssen-Cilag: Other: Advisory board; Bristol Myers Squibb: Other: Advisory board; Amgen: Consultancy, Other: Advisory Board ; Abbvie: Consultancy, Other: Advisory Board; SecuraBio: Other: Advisory board. Lahuerta Palacios: Sanofi: Honoraria; BMS: Honoraria; Janssen: Honoraria. Bladé: Celgene/Bristol Myers Squibb: Other: Honoraria for lectures; Amgen: Other: Honoraria for lectures; Janssen: Other: Honoraria for lectures; Sanofi: Other: Honoraria for lectures.

*signifies non-member of ASH